Instrument Inactif

Autres langues Eisai Co., Ltd. OTC Markets

Actions

ESALY

US2825793092

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

FDA approves a second Alzheimer's drug that can modestly slow disease	02/07
Eli Lilly Alzheimer's drug approved by US FDA	02/07
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC)	02/07
Eisai Repurchases 4.8 Billion Yen Worth of Shares in June	02/07
Tranche Update on Eisai Co., Ltd.'s Equity Buyback Plan announced on May 15, 2024.	01/07
Japan's Eisai developing dementia drug for US market, Nikkei reports	30/06
EISAI - NEW EFFICACY DATA FOR NON-CLEAR CELL RENAL CELL CARCINOMA FROM KEYNOTE-B61 ADDED TO LENVIMA US LABEL SUPPORTING KEYTRUDA + LENVIMA INDICATION FOR THE FIRST-LINE TREATMENT OF ADULT PATIENTS WITH ADVANCED RCC	28/06
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China	28/06
Eisai and Biogen launch Alzheimer's drug Leqembi in China	28/06
Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China	28/06
Leqembi[®] (lecanemab) launched in China	28/06
Periotherapia Co., Ltd. announced that it has received ¥390 million in funding from Mitsubishi UFJ Capital Co., Ltd., Eisai Co., Ltd., Techno Science, Inc., Chishima Real Estate Co., Ltd., Osaka University Venture Capital Co., Ltd.	27/06
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City	21/06
Eisai : Notification Regarding Revision of “Eisai Global Code of Conduct for Business Partners”	21/06
Biogen executive plays down looming competition for its Alzheimer's drug	12/06
BioArctic AB - FDA accepts filing of Leqembi sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease	11/06
Japan's Nikkei gains on chip shares boost; Fed policy in focus	11/06
Japan's Nikkei rises on US stocks, heavyweight chip shares	11/06
FDA advisory panel votes in favor of data for Lilly Alzheimer's drug	10/06
FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease	10/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Eisai Co., Ltd. OTC Markets

Actions

ESALY

US2825793092

Autres langues

Filtres